Historique
Article de Périodique
Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial (2013)
Auteur(s) :
MILES, S. W. ;
SHERIDAN, J. ;
RUSSELL, B. ;
KYDD, R. ;
WHEELER, A. ;
WALTERS, C. ;
GAMBLE, G. ;
HARDLEY, P. ;
JENSEN, M. ;
KUOPPASALMI, K. ;
TUOMOLA, P. ;
FÖHR, J. ;
KUIKANMAKI, O. ;
VORMA, H. ;
SALOKANGAS, R. K. ;
MIKKONEN, A. ;
KALLIO, M. ;
KAUHANEN, J. ;
KIVINIEMI, V. ;
TIIHONEN, J.
Année :
2013
Page(s) :
1279-1286
Langue(s) :
Anglais
Refs biblio. :
32
Domaine :
Drogues illicites / Illicit drugs
Thésaurus mots-clés
AMPHETAMINE
;
METHAMPHETAMINE
;
METHYLPHENIDATE
;
SUBSTITUTION
;
ETUDE RANDOMISEE
;
EFFICACITE
;
EPIDEMIOLOGIE DESCRIPTIVE
Thésaurus géographique
FINLANDE
;
NOUVELLE ZELANDE
Résumé :
Aims To assess the efficacy of methylphenidate as a substitution therapy for amphetamine/methamphetamine dependence in Finland and New Zealand. Design Parallel-group, double-blind, randomized placebo-controlled trial. Setting Out-patient care. Participants Amphetamine-/methamphetamine-dependent, aged 16-65 years. Measurements The primary outcome measure was presence/absence of amphetamine/methamphetamine in urine samples collected twice weekly. Secondary measures included treatment adherence, alterations in craving scores and self-reported use. Primary analysis was by intention-to-treat (ITT). The study drug, methylphenidate (as Concerta®), was up-titrated over 2 weeks to a maximum dose of 54 mg daily and continued for a further 20 weeks. Doses were given under daily supervision at the clinics. Findings Seventy-nine participants were randomized (40 methylphenidate; 39 placebo); 76 received allocated treatment and 27 completed the trial. ITT analysis (n = 78) showed no statistically significant difference in the percentage of positive urines between the methylphenidate and placebo arms (odds ratio: 0.95, 95% confidence interval: 0.83-1.08). However, there was a significant difference (P
HIGHLIGHTS:
Methylphenidate may improve retention of amphetamine/methamphetamine users in substance misuse treatment but any effect on substance misuse remains unproven.
HIGHLIGHTS:
Methylphenidate may improve retention of amphetamine/methamphetamine users in substance misuse treatment but any effect on substance misuse remains unproven.
Affiliation :
University of Auckland, Auckland, New Zealand
Cote :
Abonnement